Lewy body dementia

Summary

Lewy body dementia (MONDO:0007488) is a disease caused by SNCA (GenCC Strong), with 19 cohort genes (130 GWAS associations across 20 studies) and 204 clinical trials. Top therapeutic interventions include donepezil, memantine, and rivastigmine.

At a glance

• Causal gene: SNCA (GenCC Strong)
• Cohort genes: 19
• GWAS associations: 130
• ClinVar variants: 126
• Clinical trials: 204

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Lewy body dementia
Mondo ID	MONDO:0007488
EFO	EFO:0006792
OMIM	127750
Orphanet	1648
DOID	DOID:12217
ICD-10-CM	G31.83
NCIT	C84826
SNOMED CT	312991009
UMLS	C0752347
MedGen	199874
Is cancer (heuristic)	no

Also known as: cortical Lewy body disease · dementia with Lewy bodies · dementia, Lewy body · DLB · Lewy body dementia · lewy body dementia, susceptibility to · Lewy body disease

Data availability: 126 ClinVar variants · 130 GWAS associations (20 studies) · 4 GenCC gene-disease records · 44 cell lines.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › synucleinopathy › Lewy body dementia

Related subtypes (1): multiple system atrophy

Genetics & variants

GWAS landscape

130 GWAS associations across 20 studies. Top hits map to 32 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs157595	4e-145	APOC1 - APOC1P1	A	25.65
rs769449	3e-101	APOE	A	2.32
rs429358	3e-64	APOE	C	2.46
rs6733839	2e-31	BIN1 - NIFKP9	T	11.68
rs34311866	1e-27	TMEM175	C	10.89
rs1372518	3e-26	SNCA	A	10.61
rs2532307	4e-26	KANSL1	A	10.58
rs35603727	2e-21	UBQLN4	A	9.49
rs7680557	3e-17	SNCA-AS1	C	0.76
rs2230288	5e-16	GBA1	T	2.01
rs1532278	6e-14	CLU	T	7.5
rs7185007	6e-14	CTF2P - FBXL19-AS1	T	7.51
rs7681440	9e-13	SNCA	?	1.37
rs10513789	1e-12	MCCC1	G	7.08
rs111789331	7e-12	APOC1 - APOC1P1	A	2.59
rs4663105	7e-12	BIN1 - NIFKP9	A	0.82
rs894280	2e-11	SNCA-AS1	T	1.22
rs1474055	3e-10	STK39 - RN7SL813P	T	6.3
rs112017605	5e-10	LINC02929	A	3.01
rs35749011	7e-10	HMGN2P18 - KRTCAP2	G	2.27
rs13216201	9e-10	TREML2	T	6.12
rs12734374	1e-09	ASH1L	?	4.31
rs6599388	3e-09	TMEM175	T	1.15
rs620490	3e-09	MSR1 - RN7SL474P	G	5.91
rs1867598	4e-09	ELOVL7	G	5.87
rs117896735	8e-09	INPP5F	A	5.76
rs897984	1e-08	BCL7C, MIR4519, MIR762HG	?	1.3
rs12453	1e-08	MS4A6A	C	5.74
rs4389574	1e-08	BST1	A	5.68
rs9790947	2e-08	HAVCR2	T	5.61

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90705033	Zhu P	2025	3,663	5,290	Genome-wide association study provides insights into the genetic basis of Lewy body dementia.
GCST90502823	Bayram E	2024	2,591	4,023	Genetic analysis of the X chromosome in people with Lewy body dementia nominates new risk loci.
GCST90133379	Guo P	2022	2,591	4,027	Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer’s disease and Parkinson’s disease: a large-scale multi-trait association analysis.
GCST90001390	Chia R	2021	2,591	4,027	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture.
GCST90502821	Bayram E	2024	1,643	1,963	Genetic analysis of the X chromosome in people with Lewy body dementia nominates new risk loci.
GCST90093377	Kaivola K	2021	1,393	2,271	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.
GCST005276	Guerreiro R	2018	1,216	3,791	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.
GCST90093378	Kaivola K	2021	1,180	0	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.
GCST90276157	Talyansky S	2023	1,072	1,263	APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology.
GCST90276160	Talyansky S	2023	1,072	2,492	APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	5
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	44

MAF distribution

Bucket	Variants
common (>=0.05)	37
low_freq (0.01-0.05)	13
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	30
intergenic_variant	10
missense_variant	5
non_coding_transcript_exon_variant	2
unknown	2
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs157595	19	44922203	A>G,T	0.41	intergenic_variant	APOC1 - APOC1P1	4e-145	Tier 4: intronic/intergenic
rs769449	19	44906745	G>A	0.11	intron_variant	APOE	3e-101	Tier 4: intronic/intergenic
rs429358	19	44908684	T>C	0.14	missense_variant	APOE	3e-64	Tier 1: coding
rs6733839	2	127135234	C>G,T	0.362	intron_variant	BIN1 - NIFKP9	2e-31	Tier 4: intronic/intergenic
rs34311866	4	958159	T>C	0.202	missense_variant	TMEM175	1e-27	Tier 1: coding
rs1372518	4	89836143	A>C,G,T	0.234	intron_variant	SNCA	3e-26	Tier 4: intronic/intergenic
rs2532307	17	46143984	G>A,C	0.233	intron_variant	KANSL1	4e-26	Tier 4: intronic/intergenic
rs35603727	1	156038197	G>A	0.014	intron_variant	UBQLN4	2e-21	Tier 4: intronic/intergenic
rs7680557	4	89842209	C>A,G,T	0.491	non_coding_transcript_exon_variant	SNCA-AS1	3e-17	Tier 4: intronic/intergenic
rs2230288	1	155236376	C>G,T	0.013	missense_variant	GBA1	5e-16	Tier 1: coding
rs1532278	8	27608798	T>A,C	0.388	intron_variant	CLU	6e-14	Tier 4: intronic/intergenic
rs7185007	16	30916188	C>A,T	0.239	intergenic_variant	CTF2P - FBXL19-AS1	6e-14	Tier 4: intronic/intergenic
rs7681440	4	89835399	C>A,G,T	0.48	intron_variant	SNCA	9e-13	Tier 4: intronic/intergenic
rs10513789	3	183042285	T>C,G	0.201	intron_variant	MCCC1	1e-12	Tier 4: intronic/intergenic
rs111789331	19	44923868	T>A	0.1	intergenic_variant	APOC1 - APOC1P1	7e-12	Tier 4: intronic/intergenic
rs4663105	2	127133851	A>C	0.05	intron_variant	BIN1 - NIFKP9	7e-12	Tier 4: intronic/intergenic
rs894280	4	89839732	C>A,G,T	0.05	intron_variant	SNCA-AS1	2e-11	Tier 4: intronic/intergenic
rs1474055	2	168253884	C>T	0.127	intron_variant	STK39 - RN7SL813P	3e-10	Tier 4: intronic/intergenic
rs112017605	10	62580294	G>A	0.06	intron_variant	LINC02929	5e-10	Tier 4: intronic/intergenic
rs35749011	1	155162560	G>A,T	0.014	intergenic_variant	HMGN2P18 - KRTCAP2	7e-10	Tier 4: intronic/intergenic
rs13216201	6	41194322	G>T	0.301	intron_variant	TREML2	9e-10	Tier 4: intronic/intergenic
rs12734374	1	155419060	A>T	0.05	intron_variant	ASH1L	1e-09	Tier 4: intronic/intergenic
rs6599388	4	945299	C>T	0.286	intron_variant	TMEM175	3e-09	Tier 4: intronic/intergenic
rs620490	8	16840070	T>A,C,G	0.278	intron_variant	MSR1 - RN7SL474P	3e-09	Tier 4: intronic/intergenic
rs1867598	5	60842132	A>C,G	0.099	intron_variant	ELOVL7	4e-09	Tier 4: intronic/intergenic
rs117896735	10	119776815	G>A	0.014	intron_variant	INPP5F	8e-09	Tier 4: intronic/intergenic
rs897984	16	30875322	T>A,C,G	0.4	non_coding_transcript_exon_variant	BCL7C, MIR4519, MIR762HG	1e-08	Tier 4: intronic/intergenic
rs12453	11	60178272	T>C,G	0.411	missense_variant	MS4A6A	1e-08	Tier 1: coding
rs4389574	4	15728775	A>G	0.452	intron_variant	BST1	1e-08	Tier 4: intronic/intergenic
rs9790947	5	157115171	T>A,C	0.165	intergenic_variant	HAVCR2	2e-08	Tier 4: intronic/intergenic

ClinVar germline variants

126 retrieved; paginated sample, class counts are floors:

40 uncertain significance, 26 likely benign, 17 pathogenic/likely pathogenic, 16 pathogenic, 11 conflicting classifications of pathogenicity, 6 benign/likely benign, 5 likely pathogenic, 2 benign, 1 not provided, 1 conflicting classifications of pathogenicity; risk factor, 1 pathogenic/likely pathogenic; risk factor

ClinVar	Variant (HGVS)	Gene	Classification	Review
1119997	NM_000157.4(GBA1):c.604C>T (p.Arg202Ter)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1211295	NM_000157.4(GBA1):c.1249T>G (p.Trp417Gly)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1722541	NM_000157.4(GBA1):c.1361C>T (p.Pro454Leu)	GBA1	Pathogenic	no assertion criteria provided
193611	NM_000157.4(GBA1):c.1265_1319del (p.Leu422fs)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
21072	NM_000157.4(GBA1):c.703T>C (p.Ser235Pro)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4290	NM_000157.4(GBA1):c.1226A>G (p.Asn409Ser)	GBA1	Pathogenic/Likely pathogenic; risk factor	criteria provided, multiple submitters, no conflicts
4292	NM_000157.4(GBA1):c.1297G>T (p.Val433Leu)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4293	NM_000157.4(GBA1):c.1342G>C (p.Asp448His)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4295	NM_000157.4(GBA1):c.1504C>T (p.Arg502Cys)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
4298	NM_000157.4(GBA1):c.764T>A (p.Phe255Tyr)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4301	NM_000157.4(GBA1):c.754T>A (p.Phe252Ile)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4302	NM_000157.4(GBA1):c.84dup (p.Leu29fs)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
4311	NM_000157.4(GBA1):c.1604G>A (p.Arg535His)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4314	NM_000157.4(GBA1):c.680A>G (p.Asn227Ser)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
4321	NM_000157.4(GBA1):c.259C>T (p.Arg87Trp)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
4326	NM_000157.4(GBA1):c.1192C>T (p.Arg398Ter)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
4327	NM_000157.4(GBA1):c.1246G>A (p.Gly416Ser)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4328	NM_000157.4(GBA1):c.887G>A (p.Arg296Gln)	GBA1	Pathogenic	criteria provided, multiple submitters, no conflicts
632835	NM_000157.4(GBA1):c.595_596del (p.Leu199fs)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
633240	NM_000157.4(GBA1):c.762-1G>C	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
642539	NM_000157.4(GBA1):c.222_224del (p.Thr75del)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
928837	NM_000157.4(GBA1):c.914del (p.Pro305fs)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
932181	NM_000157.4(GBA1):c.661C>A (p.Pro221Thr)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
93445	NM_000157.4(GBA1):c.115+1G>A	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
987870	NM_000157.4(GBA1):c.203dup (p.Thr69fs)	GBA1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4306	NM_000157.4(GBA1):c.1085C>T (p.Thr362Ile)	LOC106627981	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
14011	NC_000004.12:g.(?89724098)(89927969_89934809)dup	LOC129389225	Pathogenic	no assertion criteria provided
14007	NM_000345.4(SNCA):c.157G>A (p.Ala53Thr)	SNCA	Pathogenic	criteria provided, multiple submitters, no conflicts
14010	NM_000345.4(SNCA):c.136G>A (p.Glu46Lys)	SNCA	Pathogenic	criteria provided, single submitter
1454898	NC_000004.11:g.(?90647779)(90756818_?)dup	SNCA	Pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 12 · Orphanet: 29 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 2

Dual-evidence genes (GWAS + Mendelian — highest-confidence targets)

Gene	HGNC	Evidence routes
SNCA	SNCA	GWAS, GenCC, Orphanet
GBA1	GBA1	GWAS, Orphanet

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
SNCA	Strong	Autosomal dominant	Lewy body dementia	10
SNCB	Moderate	Unknown	Lewy body dementia	2

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SNCA	Orphanet:171695	Parkinsonian-pyramidal syndrome
SNCA	Orphanet:2828	Young-onset Parkinson disease
SNCA	Orphanet:411602	Hereditary late-onset Parkinson disease
GBA1	Orphanet:2072	Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome
GBA1	Orphanet:411602	Hereditary late-onset Parkinson disease
GBA1	Orphanet:77259	Gaucher disease type 1
GBA1	Orphanet:77260	Gaucher disease type 2
GBA1	Orphanet:77261	Gaucher disease type 3
GBA1	Orphanet:85212	Fetal Gaucher disease
VCP	Orphanet:100070	Progressive non-fluent aphasia
VCP	Orphanet:275864	Behavioral variant of frontotemporal dementia
VCP	Orphanet:275872	Frontotemporal dementia with motor neuron disease
VCP	Orphanet:329475	Spastic paraplegia-Paget disease of bone syndrome
VCP	Orphanet:329478	Adult-onset distal myopathy due to VCP mutation
VCP	Orphanet:435387	Autosomal dominant Charcot-Marie-Tooth disease type 2Y
VCP	Orphanet:52430	Inclusion body myopathy with Paget disease of bone and frontotemporal dementia
VCP	Orphanet:803	Amyotrophic lateral sclerosis
STX1B	Orphanet:36387	Genetic epilepsy with febrile seizure plus
ASH1L	Orphanet:178469	Autosomal dominant non-syndromic intellectual disability
CTNND2	Orphanet:178469	Autosomal dominant non-syndromic intellectual disability
CTNND2	Orphanet:281	Monosomy 5p syndrome
CTNND2	Orphanet:86814	Familial adult myoclonic epilepsy
GNB5	Orphanet:542306	GNB5-related intellectual disability-cardiac arrhythmia syndrome
APOE	Orphanet:329481	Lipoprotein glomerulopathy
APOE	Orphanet:412	Dysbetalipoproteinemia
MYO7A	Orphanet:231169	Usher syndrome type 1
MYO7A	Orphanet:231178	Usher syndrome type 2
MYO7A	Orphanet:90635	Rare autosomal dominant non-syndromic sensorineural deafness type DFNA
MYO7A	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB

Cohort genes → proteins

19 cohort genes, 19 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	15
gwas_and_clinvar	1
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SNCA	HGNC:11138	ENSG00000145335	P37840	Alpha-synuclein	gwas,gencc,clinvar
SNCB	HGNC:11140	ENSG00000074317	Q16143	Beta-synuclein	gencc,clinvar
GBA1	HGNC:4177	ENSG00000177628	P04062	Lysosomal acid glucosylceramidase	gwas,clinvar
BCL7C	HGNC:1006	ENSG00000099385	Q8WUZ0	B-cell CLL/lymphoma 7 protein family member C	gwas
VCP	HGNC:12666	ENSG00000165280	P55072	Transitional endoplasmic reticulum ATPase	clinvar
PARVB	HGNC:14653	ENSG00000188677	Q9HBI1	Beta-parvin	gwas
PDLIM5	HGNC:17468	ENSG00000163110	Q96HC4	PDZ and LIM domain protein 5	gwas
STX1B	HGNC:18539	ENSG00000099365	P61266	Syntaxin-1B	gwas
ASH1L	HGNC:19088	ENSG00000116539	Q9NR48	Histone-lysine N-methyltransferase ASH1L	gwas
VPS36	HGNC:20312	ENSG00000136100	Q86VN1	Vacuolar protein-sorting-associated protein 36	gwas
FRMD3	HGNC:24125	ENSG00000172159	A2A2Y4	FERM domain-containing protein 3	gwas
CTNND2	HGNC:2516	ENSG00000169862	Q9UQB3	Catenin delta-2	gwas
GARNL3	HGNC:25425	ENSG00000136895	Q5VVW2	GTPase-activating Rap/Ran-GAP domain-like protein 3	gwas
GON4L	HGNC:25973	ENSG00000116580	Q3T8J9	GON-4-like protein	gwas
SPHKAP	HGNC:30619	ENSG00000153820	Q2M3C7	A-kinase anchor protein SPHKAP	gwas
GNB5	HGNC:4401	ENSG00000069966	O14775	Guanine nucleotide-binding protein subunit beta-5	gwas
IRF2	HGNC:6117	ENSG00000168310	P14316	Interferon regulatory factor 2	gwas
APOE	HGNC:613	ENSG00000130203	P02649	Apolipoprotein E	gwas
MYO7A	HGNC:7606	ENSG00000137474	Q13402	Unconventional myosin-VIIa	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SNCA	Alpha-synuclein	Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release.
SNCB	Beta-synuclein	Non-amyloid component of senile plaques found in Alzheimer disease.
GBA1	Lysosomal acid glucosylceramidase	Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose.
BCL7C	B-cell CLL/lymphoma 7 protein family member C	May play an anti-apoptotic role.
VCP	Transitional endoplasmic reticulum ATPase	Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis.
PARVB	Beta-parvin	Adapter protein that plays a role in integrin signaling via ILK and in activation of the GTPases CDC42 and RAC1 by guanine exchange factors, such as ARHGEF6.
PDLIM5	PDZ and LIM domain protein 5	May play an important role in the heart development by scaffolding PKC to the Z-disk region.
STX1B	Syntaxin-1B	Potentially involved in docking of synaptic vesicles at presynaptic active zones.
ASH1L	Histone-lysine N-methyltransferase ASH1L	Histone methyltransferase specifically trimethylating ‘Lys-36’ of histone H3 forming H3K36me3.
VPS36	Vacuolar protein-sorting-associated protein 36	Component of the ESCRT-II complex (endosomal sorting complex required for transport II), which is required for multivesicular body (MVB) formation and sorting of endosomal cargo proteins into MVBs.
FRMD3	FERM domain-containing protein 3	Putative tumor suppressor gene that may be implicated in the origin and progression of lung cancer.
CTNND2	Catenin delta-2	Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses.
GON4L	GON-4-like protein	Acts as a key transcription regulator of histones.
SPHKAP	A-kinase anchor protein SPHKAP	Anchoring protein that binds preferentially to the type I regulatory subunit of c-AMP-dependent protein kinase (PKA type I) and targets it to distinct subcellular compartments.
GNB5	Guanine nucleotide-binding protein subunit beta-5	Enhances GTPase-activating protein (GAP) activity of regulator of G protein signaling (RGS) proteins, such as RGS7 and RGS9, hence involved in the termination of the signaling initiated by the G protein coupled receptors (GPCRs) by acceler…
IRF2	Interferon regulatory factor 2	DNA-binding transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible genes and regulates their expression.
APOE	Apolipoprotein E	APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids.
MYO7A	Unconventional myosin-VIIa	Myosins are actin-based motor molecules with ATPase activity.

Protein-family classification

Druggable: 2 · Difficult: 5 · Unknown: 12 · Druggable fraction: 0.11

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	2	1.8×	0.478
Transcription factor	3	1.3×	0.478
Enzyme (other)	2	1.3×	0.478
Other/Unknown	12	1.1×	0.478

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SNCA	Other/Unknown	no		Synuclein, Synuclein_alpha
SNCB	Other/Unknown	no		Synuclein, Synuclein_beta
GBA1	Enzyme (other)	yes	3.2.1.45	Glyco_hydro_30, GH_hydrolase_sf, GH30_C
BCL7C	Other/Unknown	no		BCL7
VCP	Enzyme (other)	yes	3.6.4.6	CDC4_N-term_subdom, AAA+_ATPase, ATPase_AAA_core
PARVB	Other/Unknown	no		CH_dom, Parvin, CH_dom_sf
PDLIM5	Transcription factor	no		PDZ, Znf_LIM, PDZ_sf
STX1B	Other/Unknown	no		T_SNARE_dom, Syntaxin_N, Syntaxin/epimorphin_CS
ASH1L	Transcription factor	no	2.1.1.357	BAH_dom, SET_dom, Bromodomain
VPS36	Other/Unknown	no		PH-like_dom_sf, GLUE_dom, WH-like_DNA-bd_sf
FRMD3	Other/Unknown	no		FERM_domain, Ez/rad/moesin-like, PH-like_dom_sf
CTNND2	Other/Unknown	no		Armadillo, ARM-like, ARM-type_fold
GARNL3	Other/Unknown	no		Rap/Ran_GAP_dom, CNH_dom, Rap/Ran-GAP_sf
GON4L	Transcription factor	no		SANT/Myb, PAH, Homeodomain-like_sf
SPHKAP	Other/Unknown	no		SPHK1-interactor_AKAP_110, AKAP_110_C
GNB5	Scaffold/PPI	no		WD40_G-protein_beta-like, WD40_rpt, WD40/YVTN_repeat-like_dom_sf
IRF2	Other/Unknown	no		Interferon_reg_fact_DNA-bd_dom, IRF1/IRF2, Interferon_reg_fac_CS
APOE	Other/Unknown	no		ApoA_E, Apolipoprotein_A1/A4/E
MYO7A	Scaffold/PPI	no		IQ_motif_EF-hand-BS, FERM_domain, MyTH4_dom

Expression context

Cohort genes with no expression data: 0.

19 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	19
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cerebellar hemisphere	4
right hemisphere of cerebellum	3
islet of Langerhans	2
stromal cell of endometrium	2
cerebellar cortex	2
left ventricle myocardium	2
left adrenal gland	2
right adrenal gland cortex	2
orbitofrontal cortex	1
pons	1
trabecular bone tissue	1
right frontal lobe	1
placenta	1
apex of heart	1
lower esophagus mucosa	1
olfactory segment of nasal mucosa	1
adrenal tissue	1
gastrocnemius	1
hindlimb stylopod muscle	1
muscle of leg	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SNCA	280	ubiquitous	marker	trabecular bone tissue, orbitofrontal cortex, pons
SNCB	171	broad	marker	right hemisphere of cerebellum, right frontal lobe, cerebellar hemisphere
GBA1	134	ubiquitous	marker	stromal cell of endometrium, islet of Langerhans, placenta
BCL7C	262	ubiquitous	marker	lower esophagus mucosa, olfactory segment of nasal mucosa, apex of heart
VCP	294	ubiquitous	marker	stromal cell of endometrium, adrenal tissue, islet of Langerhans
PARVB	235	ubiquitous	marker	hindlimb stylopod muscle, gastrocnemius, muscle of leg
PDLIM5	295	ubiquitous	marker	biceps brachii, skeletal muscle tissue of biceps brachii, skeletal muscle tissue of rectus abdominis
STX1B	176	ubiquitous	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
ASH1L	267	ubiquitous	marker	Brodmann (1909) area 23, pylorus, cardia of stomach
VPS36	254	ubiquitous	marker	upper arm skin, ileal mucosa, skin of hip
FRMD3	250	broad	marker	secondary oocyte, kidney epithelium, left ventricle myocardium
CTNND2	213	broad	marker	cortical plate, prefrontal cortex, amygdala
GARNL3	207	ubiquitous	marker	cerebellar hemisphere, cerebellar cortex, right hemisphere of cerebellum
GON4L	255	ubiquitous	marker	sural nerve, granulocyte, colonic epithelium
SPHKAP	127	tissue_specific	marker	left ventricle myocardium, cardiac muscle of right atrium, myocardium
GNB5	279	ubiquitous	marker	middle temporal gyrus, endothelial cell, cerebellar hemisphere
IRF2	248	ubiquitous	marker	monocyte, leukocyte, mononuclear cell
APOE	267	ubiquitous	marker	left adrenal gland, left adrenal gland cortex, right adrenal gland cortex
MYO7A	186	broad	marker	right adrenal gland cortex, right adrenal gland, left adrenal gland

Protein interactions among cohort

Intra-cohort edges: 5.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
VCP	10,015
SNCA	7,615
APOE	6,793
GNB5	2,987
ASH1L	2,789
GBA1	2,568
CTNND2	2,437
IRF2	2,258
SNCB	2,157
STX1B	2,130

Intra-cohort edges

A	B	Sources
APOE	SNCA	intact, string_interaction
ASH1L	GON4L	string_interaction
GBA1	SNCA	biogrid_interaction, string_interaction
GBA1	SNCB	string_interaction
SNCA	SNCB	biogrid_interaction, intact, string_interaction

Structural data

PDB: 11 · AlphaFold-only: 8 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SNCA	P37840	232
VCP	P55072	144
GBA1	P04062	58
GNB5	O14775	32
APOE	P02649	29
ASH1L	Q9NR48	16
PARVB	Q9HBI1	3
PDLIM5	Q96HC4	3
VPS36	Q86VN1	3
IRF2	P14316	1
MYO7A	Q13402	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
STX1B	P61266	84.17
FRMD3	A2A2Y4	75.03
GARNL3	Q5VVW2	74.39
BCL7C	Q8WUZ0	63.71
SNCB	Q16143	61.29
CTNND2	Q9UQB3	58.88
GON4L	Q3T8J9	48.51
SPHKAP	Q2M3C7	47.68

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 158. Enrichment computed across 19 evidence-associated genes (14 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 14 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Toxicity of botulinum toxin type C (botC)	1	271.9×	0.097	STX1B
MTF1 activates gene expression	1	271.9×	0.097	SNCB
Attachment and Entry	1	203.9×	0.097	VCP
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	1	163.1×	0.097	VCP
DNA Damage Bypass	1	163.1×	0.097	VCP
Chylomicron clearance	1	163.1×	0.097	APOE
Neurotoxicity of clostridium toxins	1	102.0×	0.097	STX1B
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components	1	102.0×	0.097	PARVB
Hh mutants abrogate ligand secretion	1	102.0×	0.097	VCP
Chylomicron assembly	1	81.6×	0.097	APOE
Chylomicron remodeling	1	81.6×	0.097	APOE
HDL remodeling	1	81.6×	0.097	APOE
Early SARS-CoV-2 Infection Events	1	74.2×	0.097	VCP
Josephin domain DUBs	1	68.0×	0.097	VCP
Response to metal ions	1	62.8×	0.097	SNCB
Uptake and actions of bacterial toxins	1	58.3×	0.097	STX1B
LGI-ADAM interactions	1	58.3×	0.097	STX1B
Protein ubiquitination	1	58.3×	0.097	VCP
Regulated Necrosis	1	51.0×	0.097	IRF2
Plasma lipoprotein assembly	1	51.0×	0.097	APOE
Cell-extracellular matrix interactions	1	48.0×	0.097	PARVB
Protein methylation	1	48.0×	0.097	VCP
Formation of the non-canonical BAF (ncBAF) complex	1	48.0×	0.097	BCL7C
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1	45.3×	0.097	APOE
G beta:gamma signalling through BTK	1	45.3×	0.097	GNB5
Formation of the canonical BAF (cBAF) complex	1	45.3×	0.097	BCL7C
Formation of the polybromo-BAF (pBAF) complex	1	45.3×	0.097	BCL7C
Translesion Synthesis by POLH	1	42.9×	0.097	VCP
Scavenging by Class A Receptors	1	42.9×	0.097	APOE
Prostacyclin signalling through prostacyclin receptor	1	42.9×	0.097	GNB5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 18 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of protein metabolic process	2	234.1×	0.003	GBA1, APOE
positive regulation of neurotransmitter secretion	2	208.1×	0.003	SNCA, STX1B
negative regulation of platelet-derived growth factor receptor signaling pathway	2	208.1×	0.003	SNCA, APOE
negative regulation of MAPK cascade	3	50.1×	0.003	GBA1, ASH1L, APOE
synapse organization	3	46.8×	0.003	SNCA, SNCB, CTNND2
neuron apoptotic process	3	30.9×	0.007	SNCA, SNCB, GBA1
positive regulation of endocytosis	2	89.2×	0.011	SNCA, APOE
neutral lipid metabolic process	1	936.2×	0.013	SNCA
lipid transport involved in lipid storage	1	936.2×	0.013	APOE
positive regulation of SNARE complex assembly	1	936.2×	0.013	SNCA
regulation of acyl-CoA biosynthetic process	1	936.2×	0.013	SNCA
negative regulation of dopamine uptake involved in synaptic transmission	1	936.2×	0.013	SNCA
negative regulation of norepinephrine uptake	1	936.2×	0.013	SNCA
maintenance of location in cell	1	936.2×	0.013	APOE
pigment granule transport	1	936.2×	0.013	MYO7A
intermediate-density lipoprotein particle clearance	1	936.2×	0.013	APOE
flavin adenine dinucleotide catabolic process	1	936.2×	0.013	VCP
positive regulation of lipid transport across blood-brain barrier	1	936.2×	0.013	APOE
negative regulation of synaptic vesicle recycling	1	936.2×	0.013	STX1B
tarsal gland development	1	936.2×	0.013	ASH1L
uterine gland development	1	936.2×	0.013	ASH1L
positive regulation of spontaneous neurotransmitter secretion	1	936.2×	0.013	STX1B
response to desipramine	1	936.2×	0.013	SNCA
positive regulation of neuronal action potential	1	936.2×	0.013	GBA1
negative regulation of macropinocytosis	1	936.2×	0.013	STX1B
regulation of cellular response to very-low-density lipoprotein particle stimulus	1	936.2×	0.013	APOE
synaptic vesicle endocytosis	2	48.0×	0.013	SNCA, SNCB
negative regulation of neuron apoptotic process	3	18.5×	0.013	SNCA, SNCB, GBA1
regulation of glutamate secretion	1	468.1×	0.018	SNCA
cerebellar Purkinje cell layer formation	1	468.1×	0.018	GBA1

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Galantamine	Phase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 16

Druggability breadth: 5 of 19 evidence-associated genes (26%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SNCA	ESTRADIOL
GBA1	MIGALASTAT
VCP	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SNCA	31	4
GBA1	12	4
VCP	4	4
SNCB	0	0
BCL7C	0	0
PARVB	0	0
PDLIM5	0	0
STX1B	0	0
ASH1L	0	0
VPS36	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
ESTRADIOL	4	SNCA
ESTRONE	4	SNCA
TETRACYCLINE	4	SNCA
PHYTONADIONE	4	SNCA
CEFTRIAXONE	4	SNCA
FLORBETAPIR	4	SNCA
ESTRIOL	4	SNCA
RIFAMPIN	4	SNCA
TRETINOIN	4	SNCA
TESTOSTERONE	4	SNCA
BRILLIANT BLUE G	4	SNCA
BROMOCRIPTINE	4	SNCA
PERGOLIDE	4	SNCA
DOPAMINE	4	SNCA
MENADIONE	4	SNCA
GENTIAN VIOLET	4	GBA1, SNCA
SELEGILINE	4	SNCA
RETINOL	4	SNCA
MIGALASTAT	4	GBA1
GLUCONOLACTONE	4	GBA1
MIGLITOL	4	GBA1
MEXILETINE	4	GBA1
CHLORHEXIDINE	4	GBA1
TAMOXIFEN	4	GBA1
CLOTRIMAZOLE	4	VCP
GANCICLOVIR	4	VCP
HEXACHLOROPHENE	4	VCP
CURCUMIN	3	SNCA
MENATETRENONE	3	SNCA
HYPERICIN	3	SNCA

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SNCA	459	Binding:458, Functional:1
GBA1	436	Binding:403, Functional:33
VCP	120	Binding:120
ASH1L	65	Binding:63, ADMET:1, Functional:1
PDLIM5	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
GBA1	3.2.1.45	glucosylceramidase
VCP	3.6.4.6	vesicle-fusing ATPase
ASH1L	2.1.1.357	[histone H3]-lysine36 N-dimethyltransferase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SNCA	459
GBA1	436
VCP	120

Pharmacogenomics

Cohort genes with a PharmGKB record: 19; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
ESTRADIOL	4	SNCA
ESTRONE	4	SNCA
TETRACYCLINE	4	SNCA
PHYTONADIONE	4	SNCA
CEFTRIAXONE	4	SNCA
FLORBETAPIR	4	SNCA
ESTRIOL	4	SNCA
RIFAMPIN	4	SNCA
TRETINOIN	4	SNCA
TESTOSTERONE	4	SNCA
BRILLIANT BLUE G	4	SNCA
BROMOCRIPTINE	4	SNCA
PERGOLIDE	4	SNCA
DOPAMINE	4	SNCA
MENADIONE	4	SNCA
GENTIAN VIOLET	4	GBA1, SNCA
SELEGILINE	4	SNCA
RETINOL	4	SNCA
MIGALASTAT	4	GBA1
GLUCONOLACTONE	4	GBA1
MIGLITOL	4	GBA1
MEXILETINE	4	GBA1
CHLORHEXIDINE	4	GBA1
TAMOXIFEN	4	GBA1
CLOTRIMAZOLE	4	VCP
GANCICLOVIR	4	VCP
HEXACHLOROPHENE	4	VCP
CURCUMIN	3	SNCA
MENATETRENONE	3	SNCA
HYPERICIN	3	SNCA

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	SNCA, GBA1, VCP
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	16	SNCB, BCL7C, PARVB, PDLIM5, STX1B, ASH1L, VPS36, FRMD3, CTNND2, GARNL3 (+6 more)

Undrugged target profiles

16 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SNCB	0	GBA1
BCL7C	0	—
PARVB	0	—
PDLIM5	1	—
STX1B	0	—
ASH1L	65	—
VPS36	0	—
FRMD3	0	—
CTNND2	0	—
GARNL3	0	—
GON4L	0	—
SPHKAP	0	—
GNB5	0	—
IRF2	0	—
APOE	0	—
MYO7A	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 204.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	145
PHASE2	29
PHASE4	11
PHASE3	6
PHASE1/PHASE2	4
PHASE2/PHASE3	3
PHASE1	3
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00950430	PHASE4	ENROLLING_BY_INVITATION	Imaging of Brain Amyloid Plaques in the Aging Population
NCT03582488	PHASE4	ENROLLING_BY_INVITATION	Longitudinal Imaging Biomarkers of Disease Progression in DLB
NCT03924414	PHASE4	ACTIVE_NOT_RECRUITING	Trial of Parkinson’s And Zoledronic Acid
NCT05514106	PHASE4	ENROLLING_BY_INVITATION	MIBG in Aging and Neurologic Disorders
NCT05590637	PHASE4	RECRUITING	Comparing Antipsychotic Medications in LBD Over Time
NCT07284290	PHASE4	RECRUITING	Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
NCT00855686	PHASE4	COMPLETED	Memantine Versus Placebo in Parkinson’s Disease Dementia or Dementia With Lewy Bodies
NCT01023672	PHASE4	COMPLETED	Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies
NCT02345213	PHASE4	COMPLETED	A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
NCT04117178	PHASE4	COMPLETED	Monitoring Anti-Dementia Drugs by Serum Levels
NCT06263673	PHASE4	COMPLETED	Anti-Diabetic Medications to Fight PD and LBD
NCT04706910	PHASE3	RECRUITING	18F-DOPA II - PET Imaging Optimization
NCT06120049	PHASE2/PHASE3	RECRUITING	[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
NCT00209456	PHASE3	COMPLETED	Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
NCT00230997	PHASE3	COMPLETED	Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
NCT00448318	PHASE2/PHASE3	UNKNOWN	Evaluating the Effects of Music Interventions on Hospitalised People With Dementia
NCT01278407	PHASE3	COMPLETED	A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
NCT01577394	PHASE3	COMPLETED	Oculomotor Testing in the Differential Diagnosis of Dementia
NCT02928445	PHASE2/PHASE3	TERMINATED	Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
NCT05428475	PHASE3	UNKNOWN	Implementation and Evaluation of Improved Access to Medical Imaging for Geriatric Patients of The Royal Ottawa Hospital
NCT03996460	PHASE2	RECRUITING	K0706 for Patients Diagnosed With Dementia With Lewy Bodies
NCT04148391	PHASE2	ACTIVE_NOT_RECRUITING	NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson’s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
NCT04405596	PHASE1/PHASE2	NOT_YET_RECRUITING	Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
NCT04588285	PHASE2	RECRUITING	Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
NCT04760860	PHASE1/PHASE2	NOT_YET_RECRUITING	Terazosin for Dementia With Lewy Bodies
NCT04786223	PHASE2	ENROLLING_BY_INVITATION	Targeting Neuroinflammation as a Contributing Pathology in Alzheimer’s Disease Dementia and Related Dementias
NCT06537076	PHASE2	RECRUITING	Safety and Efficacy of AR1005 in Patients with Lewy Body Disease
NCT07122908	PHASE1/PHASE2	RECRUITING	The Effect of Repetitive Transcranial Magnetic Stimulation on Cognitive Improvement in Dementia With Lewy Bodies
NCT07176286	PHASE2	RECRUITING	18F-mFBG Cardiac Uptake With Lewy Body Dementia
NCT07589595	PHASE2	NOT_YET_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT00543855	PHASE2	COMPLETED	A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
NCT00598650	PHASE2	COMPLETED	A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
NCT00630500	PHASE2	COMPLETED	Efficacy and Safety of Memantine for Parkinson’s Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
NCT01503944	PHASE1/PHASE2	COMPLETED	A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
NCT02640729	PHASE2	COMPLETED	Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia
NCT02669433	PHASE2	COMPLETED	Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
NCT02702102	PHASE2	COMPLETED	Imaging Inflammation in Patients With Parkinson’s Disease Dementia or Dementia With Lewy Bodies
NCT02708186	PHASE2	COMPLETED	Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
NCT02871427	PHASE2	TERMINATED	Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
NCT02910102	PHASE2	COMPLETED	Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DONEPEZIL	4	10
MEMANTINE	4	3
RIVASTIGMINE	4	3
ZOLEDRONIC ACID ANHYDROUS	4	3
IOFLUPANE I 123	4	2
ARMODAFINIL	4	1
BOSUTINIB	4	1
DONANEMAB	4	1
FLORBETABEN F18	4	1
FLORBETAPIR F 18	4	1
FLUORODOPA F 18	4	1
FLUTEMETAMOL	4	1
FUROSEMIDE	4	1
GALANTAMINE	4	1
PIMAVANSERIN	4	1
QUETIAPINE	4	1
RAMELTEON	4	1
TERAZOSIN HYDROCHLORIDE	4	1
AMBROXOL	3	5
INTEPIRDINE	3	3
FLORBENGUANE F18	3	1
FOSGONIMETON	3	1
MICROCRYSTALLINE CELLULOSE	3	1
NEFLAMAPIMOD	2	3
NELOTANSERIN	2	3
IRSENONTRINE	2	2
PITTSBURGH COMPOUND B	2	2
FLORBENAZINE F 18	2	1
MEVIDALEN	2	1
NEVADISTINEL	2	1